TACSTD2

TACSTD2
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	2MAE, 2MVK, 2MVL
Identifiers
Aliases	TACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2, tumor-associated calcium signal transducer 2, tumor associated calcium signal transducer 2
External IDs	OMIM: 137290; MGI: 1861606; HomoloGene: 1763; GeneCards: TACSTD2; OMA:TACSTD2 - orthologs
Gene location (Human)
Chr.	Chromosome 1 (human)
End	58,577,252 bp
Gene location (Mouse)
Chr.	Chromosome 6 (mouse)
End	67,512,780 bp
RNA expression pattern
	Top expressed in
	palpebral conjunctiva; ; mucosa of pharynx; ; nasal epithelium; ; bronchial epithelial cell; ; amniotic fluid; ; oral cavity; ; gingival epithelium; ; skin of thigh; ; human penis; ; epithelium of nasopharynx;
	Top expressed in
	corneal stroma; ; lip; ; esophagus; ; skin of back; ; urothelium; ; skin of external ear; ; transitional epithelium of urinary bladder; ; cervix; ; granulocyte; ; skin of abdomen;
	More reference expression data
	; ;
	More reference expression data
Gene ontology
Molecular function	protein binding; signaling receptor activity; cadherin binding involved in cell-cell adhesion;
Cellular component	integral component of membrane; cytosol; lateral plasma membrane; membrane; plasma membrane; integral component of plasma membrane; basal plasma membrane; extracellular exosome; nucleus; extracellular space; bicellular tight junction;
Biological process	ureteric bud morphogenesis; response to stimulus; negative regulation of ruffle assembly; negative regulation of cell motility; cell surface receptor signaling pathway; negative regulation of branching involved in ureteric bud morphogenesis; cell population proliferation; regulation of epithelial cell proliferation; negative regulation of stress fiber assembly; negative regulation of substrate adhesion-dependent cell spreading; negative regulation of epithelial cell migration; visual perception; cell-cell adhesion; positive regulation of stem cell differentiation;
	Sources:Amigo / QuickGO
Orthologs
	4070
	56753
	ENSG00000184292
	ENSMUSG00000051397
	P09758
	Q8BGV3
	NM_002353
	NM_020047
	NP_002344
	NP_064431
	Wikidata
View/Edit Human	View/Edit Mouse

Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1) is a protein that in humans is encoded by the TACSTD2 gene.

This intronless gene is located at the short arm of chromosome 1 (1p32.1). It encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.

Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.

Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g., lung). Later, its expression was also described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.

Trop-2 plays a role in tumor progression by actively interacting with several key molecular signaling pathways traditionally associated with cancer development and progression. Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers. Trop-2 expression has also been described in some rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers. This overexpression is caused by deregulations at a transcriptional and posttranscriptional level.

Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells, which leads to Trop-2 being associated with tumor aggressiveness and poor prognosis. This is also confirmed by the fact, that the proliferation of tumor cells is disturbed when Trop-2 is knocked down. These facts make Trop-2 a possible prognostic biomarker to identify high-risk patients, as well as an attractive therapeutic target for late-stage diseases

This antigen is the target of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), both antibody-drug conjugates.